PMID- 34587883
OWN - NLM
STAT- MEDLINE
DCOM- 20220406
LR  - 20221207
IS  - 1875-5607 (Electronic)
IS  - 1389-5575 (Linking)
VI  - 22
IP  - 3
DP  - 2022
TI  - Effects of Urtica dioica on Metabolic Profiles in Type 2 Diabetes: A Systematic 
      Review and Meta-analysis of Clinical Trials.
PG  - 550-563
LID - 10.2174/1389557521666210929143112 [doi]
AB  - BACKGROUND: Several studies have investigated the effect of Urtica dioica (UD) 
      consumption on metabolic profiles in patients with type 2 diabetes mellitus 
      (T2DM); however, the findings are inconsistent. This systematic review and 
      meta-analysis of clinical trials were performed to summarize the evidence of the 
      effects of UD consumption on metabolic profiles in patients with T2DM. METHODS: 
      Eligible studies were retrieved from searches of PubMed, Embase, Scopus, Web of 
      Science, Cochrane Library, and Google Scholar databases until December 2019. 
      Cochran (Q) and I-square statistics were used to examine heterogeneity across 
      included clinical trials. Data were pooled using a fixed-effect or random-effects 
      model and expressed as weighted mean difference (WMD) and 95% confidence interval 
      (CI). RESULTS: Among 1485 citations, thirteen clinical trials were found to be 
      eligible for the current metaanalysis. UD consumption significantly decreased 
      levels of fasting blood glucose (FBG) (WMD = - 17.17 mg/dl, 95% CI: -26.60, 
      -7.73, I2 = 93.2%), hemoglobin A1c (HbA1c) (WMD = -0.93, 95% CI: - 1.66, -0.17, 
      I2 = 75.0%), C-reactive protein (CRP) (WMD = -1.09 mg/dl, 95% CI: -1.64, -0.53, 
      I2 = 0.0%), triglycerides (WMD = -26.94 mg/dl, 95 % CI = [-52.07, -1.82], P = 
      0.03, I2 = 90.0%), systolic blood pressure (SBP) (WMD = -5.03 mmHg, 95% CI = 
      -8.15, -1.91, I2 = 0.0%) in comparison to the control groups. UD consumption did 
      not significantly change serum levels of insulin (WMD = 1.07 muU/ml, 95% CI: 
      -1.59, 3.73, I2 = 63.5%), total-cholesterol (WMD = -6.39 mg/dl, 95% CI: -13.84, 
      1.05, I2 = 0.0%), LDL-cholesterol (LDL-C) (WMD = -1.30 mg/dl, 95% CI: -9.95, 
      7.35, I2 = 66.1%), HDL-cholesterol (HDL-C) (WMD = 6.95 mg/dl, 95% CI: -0.14, 
      14.03, I2 = 95.4%), body max index (BMI) (WMD = -0.16 kg/m2, 95% CI: -1.77, 1.44, 
      I2 = 0.0%), and diastolic blood pressure (DBP) (WMD = -1.35 mmHg, 95% CI: -2.86, 
      0.17, I2= 0.0%) among patients with T2DM. CONCLUSION: UD consumption may result 
      in an improvement in levels of FBS, HbA1c, CRP, triglycerides, and SBP, but did 
      not affect levels of insulin, total-, LDL-, and HDL-cholesterol, BMI, and DBP in 
      patients with T2DM.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Tabrizi, Reza
AU  - Tabrizi R
AD  - Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, 
      Fasa, Iran.
AD  - Clinical Research Development Unit of Vali Asr Hospital, Fasa University of 
      Medical Sciences, Fasa, Iran.
FAU - Sekhavati, Eghbal
AU  - Sekhavati E
AD  - Larestan University of Medical Sciences, Larestan, Fars, Iran.
FAU - Nowrouzi-Sohrabi, Peyman
AU  - Nowrouzi-Sohrabi P
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Department of Biochemistry, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Rezaei, Shahla
AU  - Rezaei S
AD  - Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
AD  - Department of Clinical Nutrition, School of Health & Nutrition, Shiraz University 
      of Medical Sciences, Shiraz, Iran.
FAU - Tabari, Parinaz
AU  - Tabari P
AD  - Clinical Education Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Ghoran, Salar Hafez
AU  - Ghoran SH
AD  - Department of Chemistry, Faculty of Basic Sciences, Golestan University, Gorgan, 
      Iran.
AD  - Department of Medical Nanotechnology, School of Advanced Medical Sciences and 
      Technologies, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Jamali, Navid
AU  - Jamali N
AD  - Department of Biochemistry, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Jalali, Mohammad
AU  - Jalali M
AD  - Nutrition Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
FAU - Moosavi, Mahsa
AU  - Moosavi M
AD  - Clinical Education Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran.
FAU - Kolahi, Ali-Asghar
AU  - Kolahi AA
AD  - Social Determinants of Health Research Center, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Bettampadi, Deepti
AU  - Bettampadi D
AD  - Center for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt 
      Cancer Center and Research Institute, Tampa, FL 33612, USA.
FAU - Sahebkar, Amirhossein
AU  - Sahebkar A
AD  - Applied Biomedical Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad 
      University of Medical Sciences, Mashhad, Iran | School of Pharmacy, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
FAU - Safiri, Saeid
AU  - Safiri S
AD  - Research Center for Integrative Medicine in Aging, Aging Research Institute, 
      Tabriz University of Medical Sciences, Tabriz, Iran.
AD  - Department of Community Medicine, Faculty of Medicine, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
AD  - Department of Persian Medicine, School of Traditional Medicine, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
LA  - eng
GR  - 21999/Shahid Beheshti University of Medical Sciences/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - Netherlands
TA  - Mini Rev Med Chem
JT  - Mini reviews in medicinal chemistry
JID - 101094212
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Blood Glucose/analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Glycated Hemoglobin/analysis/metabolism/therapeutic use
MH  - Humans
MH  - Metabolome
MH  - Triglycerides
MH  - *Urtica dioica
OTO - NOTNLM
OT  - Anti-diabetic
OT  - Urtica dioica
OT  - blood glucose
OT  - insulin
OT  - meta analysis
OT  - metabolic profiles
OT  - type 2 diabetes mellitus
EDAT- 2021/10/01 06:00
MHDA- 2022/04/07 06:00
CRDT- 2021/09/30 05:34
PHST- 2020/09/28 00:00 [received]
PHST- 2021/02/25 00:00 [revised]
PHST- 2021/08/09 00:00 [accepted]
PHST- 2021/10/01 06:00 [pubmed]
PHST- 2022/04/07 06:00 [medline]
PHST- 2021/09/30 05:34 [entrez]
AID - MRMC-EPUB-118237 [pii]
AID - 10.2174/1389557521666210929143112 [doi]
PST - ppublish
SO  - Mini Rev Med Chem. 2022;22(3):550-563. doi: 10.2174/1389557521666210929143112.